Primary resistance to anti-tuberculosis drugs in Addis Ababa, Ethiopia

被引:0
|
作者
Demissie, M
Gebeyehu, M
Berhane, Y
机构
[1] MINIST HLTH,NATL TB & LEPROSY CONTROL PROGRAMME,ADDIS ABABA,ETHIOPIA
[2] UNIV ADDIS ABABA,FAC MED,DEPT COMMUNITY HLTH,ADDIS ABABA,ETHIOPIA
关键词
drug resistance; tuberculosis; Ethiopia;
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
OBJECTIVE: To obtain current, representative information on current drug resistance patterns in Addis Ababa, Ethiopia. DESIGN: A cross-sectional study whereby 167 isolates were tested for susceptibility to the anti-tuberculosis drugs commonly used in the country (isoniazid, thiacetazone, rifampicin, streptomycin and ethambutol). All hospitals, health centres and 6 of the 9 clinics in Addis Ababa were included in the study. RESULT: Overall primary drug resistance was found to be 15.6% (26/167). Primary resistance to two or more drugs was 7.2% (12/167). The highest rate of primary resistance was to streptomycin (10.2%) followed by isoniazid (8.4%). Resistance to rifampicin was low (1.8%, 3/167) and to ethambutol nil. Multiple drug resistance in combinations with rifampicin was low. CONCLUSION: TO prevent further development and spread of resistance, universal use of standard treatment protocol, control of the circulation of anti-tuberculosis drugs, training of health workers, expansion of strictly supervised short-course treatment and establishing a nation-wide and regular surveillance system are recommended.
引用
收藏
页码:64 / 67
页数:4
相关论文
共 50 条
  • [31] Barriers and enablers in the management of tuberculosis treatment in Addis Ababa, Ethiopia: a qualitative study
    Mette Sagbakken
    Jan C Frich
    Gunnar Bjune
    [J]. BMC Public Health, 8
  • [32] DUTCH EMBASSY IN ADDIS ABABA, ETHIOPIA
    Blanco Agueira, Silvia
    [J]. EN BLANCO-REVISTA DE ARQUITECTURA, 2012, 4 (10): : 46 - 55
  • [33] Risk factors for tuberculosis: A case-control study in Addis Ababa, Ethiopia
    Shimeles, Ezra
    Enquselassie, Fikre
    Aseffa, Abraham
    Tilahun, Melaku
    Mekonen, Alemayehu
    Wondimagegn, Getachew
    Hailu, Tsegaye
    [J]. PLOS ONE, 2019, 14 (04):
  • [34] Barriers and enablers in the management of tuberculosis treatment in Addis Ababa, Ethiopia: a qualitative study
    Sagbakken, Mette
    Frich, Jan C.
    Bjune, Gunnar
    [J]. BMC PUBLIC HEALTH, 2008, 8 (1)
  • [35] Rifampicin-Resistant Mycobacterium tuberculosis Among Patients with Presumptive Tuberculosis in Addis Ababa, Ethiopia
    Araya, Shambel
    Negesso, Abebe Edao
    Tamir, Zemenu
    [J]. INFECTION AND DRUG RESISTANCE, 2020, 13 : 3451 - 3459
  • [36] ANTI-TUBERCULOSIS DRUGS USED IN COMBINATIONS
    不详
    [J]. HSMHA HEALTH REPORTS, 1971, 86 (10): : 896 - &
  • [37] Cause Of Anti-Tuberculosis Drugs Discontinuation
    Ohashi, K.
    Takamori, M.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [38] PREMATURE EJACULATION WITH ANTI-TUBERCULOSIS DRUGS
    Chityala, Surendra K.
    [J]. RESPIROLOGY, 2013, 18 : 40 - 40
  • [39] ACTIVITY AND EFFECTIVENESS OF ANTI-TUBERCULOSIS DRUGS
    GROSSET, J
    [J]. LYON MEDICAL, 1979, 241 (09): : 567 - 573
  • [40] Delayed hypersensitivity to anti-tuberculosis drugs
    Tetart, F.
    [J]. REVUE FRANCAISE D ALLERGOLOGIE, 2020, 60 (04): : 248 - 249